Certain Options of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.
September 17, 2022
Share
Certain Options of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022. These Options will be under lockup for 180 days starting from 22-MAR-2022 to 18-SEP-2022.
Details:
The Company officers and directors have agreed that, for a period of 180 days from the date of this Prospectus Supplement, the company and they will not, without the prior written consent of EF Hutton, (I) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act with respect to any Units, Pre-Funded Units, shares of Common Stock, One-Year Warrants, Five-Year Warrants or Pre-Funded Warrants or any securities convertible into, or exercisable, or exchangeable for, shares of Common Stock,(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Units, Pre-Funded Units, shares of Common Stock, One-Year Warrants, Five-Year Warrants or Pre-Funded Warrants or any securities convertible into, or exercisable, or exchangeable for, shares of Common Stock, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (iii) publicly announce any intention to effect any transaction specified in clause (i) or (ii), subject to certain exceptions. EF Hutton, in its sole discretion, may release any of the securities subject to the lock-up agreement at any time without notice, other than in the case of the officers and directors, which shall be with notice.
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodyâs immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâs disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.